Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Northwest Biotherapeutics (NWBO) EPS (Weighted Average and Diluted) (2016 - 2025)

Northwest Biotherapeutics (NWBO) has 15 years of EPS (Weighted Average and Diluted) data on record, last reported at -$0.02 in Q3 2025.

  • For Q3 2025, EPS (Weighted Average and Diluted) changed 0.0% year-over-year to -$0.02; the TTM value through Sep 2025 reached -$0.07, up 36.36%, while the annual FY2024 figure was -$0.07, 16.67% down from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.02 in Q3 2025 per NWBO's latest filing, roughly flat from -$0.02 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at -$0.01 in Q2 2021 and bottomed at -$4.94 in Q1 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.28, with a median of -$0.02 recorded in 2023.
  • The widest YoY moves for EPS (Weighted Average and Diluted): up 99.8% in 2022, down 400.0% in 2022.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.02 in 2021, then fell by 0.0% to -$0.02 in 2022, then tumbled by 150.0% to -$0.05 in 2023, then soared by 60.0% to -$0.02 in 2024, then grew by 0.0% to -$0.02 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Weighted Average and Diluted) were -$0.02 in Q3 2025, -$0.02 in Q2 2025, and -$0.01 in Q1 2025.